Skip to main content

Table 3 Characteristics of patients with HR positive and HR negative tumor

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

  HR* positive tumor HR negative tumor
Factors BP group
N = 202
Non-BP group
N = 28
P-value|| BP group
N = 60
Non-BP group
N = 27
P-value||
Age (yr, median, range) 46 (28–77) 50.5 (33–68) NS** 43.5 (25–69) 50 (30–67) NS
PS*** (ECOG ≥ 2) 9/138 (6.5%) 0/16 (0%) NS 1/28 (3.6%) 2/11 (18.2%) NS
Pre-menopausal 66/144(45.8%) 4/18 (22.2%) 0.057 13/32 (40.6%) 3/12 (25%) NS
Post-menopausal 78/144(54.2%) 14/18 (77.8%)   19/32 (59.4%) 9/12 (75%)  
HER2 positive 44 (21.8%) 12 (42.9%) 0.015 28 (46.7%) 11 (40.7%) NS
DFI (months, median, range) 27.5 (0–230) 26 (82.1%) NS 18.5 (0–86) 18 (0–174) NS
Initial stage IV 44 (21.8%) 4 (14.3%) NS 17 (28.8%) 7 (25.9%) NS
Adjuvant treatment       
   Radiotherapy 82 (40.6%) 15 (53.6%) NS 29 (48.3%) 12 (44.4%) NS
   Chemotherapy 139 (68.8%) 21 (75%) NS 37 (61.7%) 17 (63%) NS
   Hormonal therapy 114 (56.4%) 17 (60.7%) NS 13 (21.7%) 4 (14.8%) NS
Metastatic sites       
   Visceral (liver, lung) 80 (39.6%) 18 (64.3%) 0.013 36 (60%) 19 (70.4%) NS
   LNs 87 (43.1%) 12 (42.9%) NS 32 (53.3%) 18 (66.7%) NS
   Soft tissue 57 (28.2%) 8 (28.6%) NS 21 (35%) 12 (44.4%) NS
   Bone only 73 (36.1%) 6 (21.4%) NS 8 (13.3%) 2 (7.4%) NS
   Weight bearing bone involvement 174 (86.6%) 13 (46.4%) < 0.001 51 (85%) 12 (44.4%) < 0.001
   Sum of metastatic sites (range) 2 (1–6) 3 (1–5) NS 3 (1–5) 3 (1–6) NS
Cycles of palliative chemotherapy    NS    NS
   1 27 (13.4%) 4 (14.3%)   9 (15%) 4 (14.8%)  
   2 43 (21.3%) 3 (10.7%)   10 (16.7%) 10 (37%)  
   ≥ 3 116 (57.4%) 17 (60.7%)   41 (68.3%) 12 (44.4%)  
Palliative AI§ use 159 (78.7%) 21 (75%) NS 9 (15%) 2 (7.4%) NS
Palliative anti-HER2 therapy 35/44 (79.5%) 10/12 (83.3%) NS 23/28 (82.1%) 10/11 (90.9%) NS
Disease progression in bone 96 (47.5%) 10 (35.7%) NS 23 (38.3%) 6 (22.2%) NS
SREs (except the first event) 59 (29.2%) 4 (14.3%) NS 15 (25%) 4 (14.8%) NS
  1. Abbreviations: *, hormone receptor; **, not significant; ***, performance status; †, disease free interval; ‡, lymph nodes;
  2. § aromatase inhibitor; ||, P-value was obtained via chi-square test except variables of age and DFI which were obtained through Mann-Whitney U test.